Post-hoc analysis of Kyntheum data shows benefits over ustekinumab in psoriasis

LEO Pharma announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with Kyntheum (brodalumab) maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks. The post-hoc analysis of the AMAGINE-2 and AMAGINE-3 studies – which included 3,712 people with moderate-to-severe psoriasis – shows that 90% of patients treated with brodalumab who achieved PASI 100 also experienced sustained PASI 100.

In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI 100 also experienced sustained PASI 100. Study authors measured ‘sustained PASI 100’ as the time to inadequate response, based on a static physician’s global assessment (sPGA) of at least 3 or persistent values of 2 over at least a 4-week period at or after week 16. Because the sub-populations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the study authors did not apply statistical comparisons.

Comment: These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab.

Visit our Psoriasis Knowledge Centre to find out more.